#1 Clinical Trials Search in Europe
Colorectal cancer metastatic – Trials in Disease
# Clinical Trials for Metastatic Colorectal Cancer
Metastatic colorectal cancer is a serious condition where cancer spreads from the colon or rectum to other parts of the body. Currently, 80 clinical trials are investigating new treatments and treatment combinations for patients with this disease. These studies are exploring various approaches including chemotherapy combinations, immunotherapy, targeted therapies, and novel experimental treatments to improve outcomes for patients whose cancer has spread beyond its original location.
Clinical trial locations
-
Austria
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
-
Belgium
- Study on ABBV-400 with Fluorouracil, Folinic Acid, and Bevacizumab for Adults with Unresectable Metastatic Colorectal Cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study on EO4010 Vaccine with Nivolumab and Bevacizumab for Patients with Metastatic Colorectal Cancer Who Have Already Received Treatment
- Study on Avelumab and Cetuximab for Patients with Metastatic Colorectal Cancer Who Have Previously Received Treatment
- Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer
- Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy
- Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials
- Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer
-
Czechia
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy
- Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials
- Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors
-
Denmark
- Study on Using ctDNA to Guide Treatment in Patients with Metastatic Colorectal Cancer Using Oxaliplatin, Capecitabine, Calcium Folinate, Irinotecan, and Fluorouracil
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy
- Study on Tocotrienol and Bevacizumab for Patients with Metastatic Colorectal Cancer
- Finland
-
France
- Study of Atezolizumab with Drug Combination for Patients with Unresectable Metastatic Colorectal Cancer
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Pembrolizumab, Dendritic Cell Vaccine, Trifluridine/Tipiracil, and Bevacizumab for Patients with Metastatic Colorectal Cancer
- Study on Regorafenib with Capecitabine, Cyclophosphamide, and Aspirin for Patients with Metastatic Colorectal Cancer Resistant to Chemotherapy
- Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer
- Study on the Effect of Post-Surgery Chemotherapy with Irinotecan and Drug Combination for Patients with Colorectal Cancer and Liver Metastases
- Study on the Safety of Trifluridine/Tipiracil for Patients with Dihydropyrimidine Dehydrogenase Deficiency and Metastatic Colorectal or Gastroesophageal Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy
- Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer
- See more trials
-
Germany
- Study on Bevacizumab, Encorafenib, and Cetuximab for Patients with BRAF-V600E Mutated Metastatic Colorectal Cancer
- Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer
- Study of Arfolitixorin, 5-Fluorouracil, Oxaliplatin, and Bevacizumab for Patients with Metastatic Colorectal Cancer
- Study Comparing Sacituzumab Govitecan with Standard Treatment for Patients with Metastatic Colorectal Cancer
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation
- Study on Using ctDNA to Guide Treatment in Patients with Metastatic Colorectal Cancer Using Oxaliplatin, Capecitabine, Calcium Folinate, Irinotecan, and Fluorouracil
- Safety Study of Tumor-Infiltrating Lymphocyte (TIL) Therapy for Patients with Metastatic Colorectal or Prostate Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- See more trials
-
Greece
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials
-
Hungary
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study on the Effects of Different Dosing Schedules of Irinotecan Hydrochloride, Calcium Folinate, and Fluorouracil in Patients with Metastatic Colorectal Cancer
- Study Comparing XL092 and Atezolizumab with Regorafenib for Patients with Metastatic Colorectal Cancer
- Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials
- Study of ZN-c3, Encorafenib, and Cetuximab for Adults with Metastatic Colorectal Cancer
- Ireland
-
Italy
- Study of Atezolizumab with Drug Combination for Patients with Unresectable Metastatic Colorectal Cancer
- Study of Dendritic Cell Vaccine and Aldesleukin Treatment in Patients After Surgery for Stage IV Colorectal Cancer
- Study of Galunisertib and Capecitabine for Patients with Advanced Chemotherapy-Resistant Colorectal Cancer with Peritoneal Metastases
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Pembrolizumab, Dendritic Cell Vaccine, Trifluridine/Tipiracil, and Bevacizumab for Patients with Metastatic Colorectal Cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study of Valproic Acid, Panitumumab, and Irinotecan for Patients with Metastatic Colorectal Cancer with RAS/BRAF Wild-Type
- Study on Retreatment with Encorafenib and Cetuximab for Patients with BRAF V600E Mutated Metastatic Colorectal Cancer
- Study on Cetuximab and Drug Combination for Patients with Metastatic Colorectal Cancer
- Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors
- See more trials
- Latvia
-
Netherlands
- Study of LB-100 and Azenosertib for Patients with Metastatic Colorectal Cancer
- Dose-Reduced Oxaliplatin and Drug Combination Study for Older Patients with Metastatic Colorectal Cancer
- Study of Galunisertib and Capecitabine for Patients with Advanced Chemotherapy-Resistant Colorectal Cancer with Peritoneal Metastases
- Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer
- Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
- Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability
- Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with
Ongoing Clinical Trials on Colorectal cancer metastatic
Connected medications:
- Zimberelimab
- Vinorelbine Tartrate
- Vinorelbine
- Venetoclax
- Vemurafenib
- Valproic Acid
- Ucp2
- Tucatinib
- Trastuzumab
- Trifluridine
- Tremelimumab
- Trastuzumab Deruxtecan
- Tocotrienol
- Tisotumab Vedotin
- Tislelizumab
- Tipiracil Hydrochloride
- Tipiracil
- Tinzaparin Sodium
- Temozolomide
- Talazoparib
- Sunitinib
- Sotorasib
- Sirexatamab
- Relatlimab
- Regorafenib
- Ramucirumab
- Quemliclustat
- Pf-07220060 Monohydrate
- Pertuzumab
- Petosemtamab
- Pelareorep
- Pembrolizumab
- Panobinostat
- Panitumumab
- Palbociclib
- Oxaliplatin
- Omp12
- Omp11
- Omp10
- Ondansetron
- OMTX705
- Nivolumab
- Niraparib
- Napabucasin
- N-[4-Bromo-2-(1H-1,2,3,4-Tetrazol-5-Yl)Phenyl]-N’-[3,5- Bis(Trifluoromethyl)Phenyl]Urea
- N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
- Mva-209-Fsp-B4
- Mva-209-Fsp-B3
- Mva-209-Fsp-B2
- Mva-209-Fsp-B1
- Mitomycin
- Mk-1084
- Methotrexate
- Methadone Hydrochloride
- Mesna
- Melphalan
- Magrolimab
- Letrozole
- Lapatinib
- Irinotecan Hydrochloride Trihydrate
- Irinotecan Hydrochloride
- Irinotecan
- Ict01
- Idelalisib
- Gemcitabine
- Galunisertib
- Gad20-209-Fsp-A4
- Gad20-209-Fsp-A3
- Gad20-209-Fsp-A2
- Gad20-209-Fsp-A1
- Fulvestrant
- FRUQUINTINIB
- Folinic Acid
- Fluorouracil Sodium
- Fluorouracil
- Favezelimab
- Fadraciclib
- Everolimus
- Etrumadenant
- Eo2318
- Eo2317
- Encorafenib
- Durvalumab
- Disodium Folinate
- Dasatinib
- D,L-Lysine Acetylsalicylate
- Cyclophosphamide Monohydrate
- Cyc140 Monohydrochloride Monohydrate
- Crizotinib
- Cobimetinib
- Cisplatin
- Cetuximab
- Carboplatin
- Capecitabine
- Calcium Levofolinate
- Calcium Folinate Pentahydrate
- Calcium Folinate
- Cabozantinib
- BNT327
- Bnt314
- Binimetinib
- Bevacizumab
- Azenosertib
- Avelumab
- Autologous Tumor Lysate-Loaded Dendritic Cells
- Atezolizumab
- ARFOLITIXORIN
- Anhydrous Cyclophosphamide
- Alectinib Hydrochloride
- Alectinib
- Aldesleukin
- Aflibercept
- Adagrasib
- 3-(4-Methylpiperazine-1-Carbonyl)-7-Oxabiclo[2.2.1]Heptane-2-Carboxylic Acid